Using recombinant activated blood coagulation factor VIi for treatment of hemorrhagic syndrome in patients with thrombocytopenia
Galstian, G.M.; Kolosova, I.V.
Anesteziologiia i Reanimatologiia 59(6): 60-66
2014
ISSN/ISBN: 0201-7563 PMID: 25831706 Document Number: 672984
The review deals with an analysis of the use of recombinant activated factor clotting VII (rFVIIa) for the treatment of hemorrhagic syndrome in patients with thrombocytopenia. The review discusses cases of rFVIIa use during bleeding of different localization and different invasive interventions, a frequency of thrombotic complications and causes of the rFVlIIa insufficiency.
Document emailed within 1 workday
Related Documents
Maruyama, I. 1999: Recombinant thrombomodulin and activated protein C in the treatment of disseminated intravascular coagulation Thrombosis and Haemostasis 82(2): 718-721Ashkinazi, I.I.; Klemina, I.K. 1970: The effect of activated Hageman factor on the blood coagulation system in vivo Biulleten' Eksperimental'noi Biologii i Meditsiny 69(4): 32-36
Ingerslev, J.; Thykjaer, H.; Kudsk Jensen, O.; Fredberg, U. 1998: Home treatment with recombinant activated factor VII: results from one centre Blood Coagulation and Fibrinolysis: An International Journal in Haemostasis and Thrombosis 9(Suppl 1): S107-S110
Grinţescu, I.; Tulbure, D.; Mirea, L. 2006: Activated recombinant factor VIi (Novoseven) in multiple trauma patients: an outcome analysis Chirurgia 101(6): 615-624
Guillet, B.; Pinganaud, C.; Proulle, V.; Dreyfus, M.; Lambert, T. 2002: Myocardial infarction occurring in a case of acquired haemophilia during the treatment course with recombinant activated factor VIi Thrombosis and Haemostasis 88(4): 698-699
Fukutake, K. 2000: Current status of hemophilia patients and recombinant coagulation factor concentrates in Japan Seminars in Thrombosis and Hemostasis 26(1): 29-32
Kącka, K.; Kącki, W.; Merak, J.; Błęka, A. 2010: Use of recombinant activated factor VII for reduction of perioperative blood loss during elective surgical correction of spine deformity in a Jehovah's Witness. Case report Ortopedia, Traumatologia, Rehabilitacja 12(5): 448-458
Dorofeeva, R.P.; Safonova, L.G. 1970: Blood coagulation system indices in protracted forms of infectious hepatitis with pronounced hemorrhagic syndrome Sovetskaia Meditsina 33(7): 31-35
Bunin, K.V.; Abdurashitov, R.F.; Sunargulov, T.S. 1977: Role of intravascular blood coagulation and the intravital morphological changes in the skin capillaries in pathogenesis of hemorrhagic fever with nephrotic syndrome Terapevticheskii Arkhiv 49(10): 126-130
Seidlová, D.; Blatný, J.; Penka, M.; Ovesná, P.; Brabec, P.; Sevcík, P.; Ventruba, P.; Cerný, V. 2010: Recombinant activated factor VIi in the treatment of life threatening post-partum haemorrhage; registry UniSeven in the Czech Republic Ceska Gynekologie 75(4): 297-305
Vyhovs'ka, I.I.; Karol', I.S.; Fedak, L.M.; Tsytsyk, O.I. 2004: Use of recombinant activated factor VIi (NovoSeven) in the treatment of a patient with idiopathic thrombocytopenic purpura complicated with subarachnoid and parenchimatous hemorrhage Likars'ka Sprava 7: 77-81
Kjalke, M.; Monroe, D.M.; Hoffman, M.; Oliver, J.A.; Ezban, M.; Hedner, U.; Roberts, H.R. 1998: The effects of activated factor VIi in a cell-based model for tissue factor-initiated coagulation Blood Coagulation and Fibrinolysis: An International Journal in Haemostasis and Thrombosis 9(Suppl 1): S21-S25
Osterud, B.; Kasper, C.K.; Lavine, K.K.; Prodanos, C.; Rapaport, S.I. 1981: Purification and properties of an abnormal blood coagulation factor IX (factor IXBm)/kinetics of its inhibition of factor X activation by factor VIi and bovine tissue factor Thrombosis and Haemostasis 45(1): 55-59
Devecioğlu, O.; Unüvar, A.şe.ül.; Anak, S.; Bilge, I.; Ander, H.; Ziylan, O. 2003: Pyelolithotomy in a patient with Glanzmann thrombasthenia and antiglycoprotein IIb/IIIa antibodies: the shortest possible duration of treatment with recombinant activated factor VIi and platelet transfusions Turkish Journal of Pediatrics 45(1): 64-66
Espevik, T.; Figari, I.S.; Ranges, G.E.; Palladino, M.A. 1988: Transforming growth factor-beta 1 (TGF-beta 1) and recombinant human tumor necrosis factor-alpha reciprocally regulate the generation of lymphokine-activated killer cell activity. Comparison between natural porcine platelet-derived TGF-beta 1 and TGF-beta 2, and recombinant human TGF-beta 1 Journal of Immunology 140(7): 2312-2316
He, W.J.; Hu, Y.; Zhang, X.P.; Hong, M.; Guo, T.; Wei, W.N.; Song, S.J. 2008: Activated protein C ratio, plasma tissue factor activity and activated factor VIi in Chinese patients with coronary heart disease European Journal of Medical Research 13(2): 47-51
Xu, Y.-H.; Chen, Z.-W.; Ye, X.-Y.; Lu, S. 2008: Evaluation of recombinant human thrombopoietin in the treatment of chemotherapy-induced thrombocytopenia in lung cancer patients Zhonghua Zhong Liu Za Zhi 30(9): 716-719
Holme, P.A.; Solum, N.O.; Brosstad, F.; Røger, M.; Abdelnoor, M. 1994: Demonstration of platelet-derived microvesicles in blood from patients with activated coagulation and fibrinolysis using a filtration technique and western blotting Thrombosis and Haemostasis 72(5): 666-671
Drize, N.; Chertkov, J.; Zander, A. 1995: Hematopoietic progenitor cell mobilization into the peripheral blood of mice using a combination of recombinant rat stem cell factor (rrSCF) and recombinant human granulocyte colony-stimulating factor (rhG-CSF) Experimental Hematology 23(11): 1180-1186
Takayama, K. 1993: Changes in endothelial vasoactive substances and blood coagulation and fibrinolysis functions under recombinant human erythropoietin therapy in hemodialysis patients Nihon Jinzo Gakkai Shi 35(2): 179-188